Related references
Note: Only part of the references are listed.Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database
Hannah Grace Abraham et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Inflammatory Breast Cancer: a Separate Entity
Jennifer M. Rosenbluth et al.
CURRENT ONCOLOGY REPORTS (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program
Juanjuan Li et al.
ONCOTARGET (2017)
Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptornegative inflammatory breast cancer cells
Scott J. Sauer et al.
CARCINOGENESIS (2017)
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging
Mahul B. Amin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Initial Response to Chemotherapy, Not Delay in Diagnosis, Predicts Overall Survival in Inflammatory Breast Cancer Cases
Heather J. Hoffman et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2014)
Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database
Natasha M. Rueth et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization
Kevin P. Williams et al.
CANCER LETTERS (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment
S. Dawood et al.
ANNALS OF ONCOLOGY (2011)
Case 17-2011: A 49-Year-Old Woman with a Mass in the Breast and Overlying Skin Changes
Beth A. Overmoyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inflammatory Breast Cancer: New Hopes and Many Hurdles
Karen Rowan
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Prognostic significance of HER-2 status in women with inflammatory breast cancer
Shaheenah Dawood et al.
CANCER (2008)
The epidemiology of inflammatory breast cancer
Paul H. Levine et al.
SEMINARS IN ONCOLOGY (2008)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer
G Gruber et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Share Paper
